» Articles » PMID: 35575214

Mapping the Risk of Infections in Patients with Multiple Sclerosis: A Multi-database Study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2022 May 16
PMID 35575214
Authors
Affiliations
Soon will be listed here.
Abstract

Background: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors include underlying disease, physical impairment and use of some disease-modifying treatments.

Objective: To quantify changes in population-level infection rates among pwMS and compare these to the general population and people with rheumatoid arthritis (pwRA), and identify patient characteristics predictive of infections after MS diagnosis.

Methods: We conducted a multi-database study using data on 23,226 people with MS diagnosis from the UK Clinical Practice Research Datalink Aurum and GOLD (January 2000-December 2020). PwMS were matched to MS-free controls and pwRA. We calculated infection rates, and estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) of predictors for infections ⩽ 5 years after MS diagnosis using Poisson regression.

Results: Among pwMS, overall infection rates remained stable - 1.51-fold (1.49-1.52) that in MS-free controls and 0.87-fold (0.86-0.88) that in pwRA - although urinary tract infection rate per 1000 person-years increased from 98.7 (96.1-101) (2000-2010) to 136 (134-138) (2011-2020). Recent infection before MS diagnosis was most predictive of infections (1 infection: IRR 1.92 (1.86-1.97); ⩾2 infections: IRR 3.00 (2.89-3.10)).

Conclusion: The population-level elevated risk of infection among pwMS has remained stable despite the introduction of disease-modifying treatments.

Citing Articles

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

Lal A, Foong Y, Sanfilippo P, Spelman T, Rath L, Levitz D J Neurol. 2024; 271(9):5813-5824.

PMID: 38935148 PMC: 11377668. DOI: 10.1007/s00415-024-12518-7.

References
1.
Francis N, Hood K, Lyons R, Butler C . Understanding flucloxacillin prescribing trends and treatment non-response in UK primary care: a Clinical Practice Research Datalink (CPRD) study. J Antimicrob Chemother. 2016; 71(7):2037-46. PMC: 4896409. DOI: 10.1093/jac/dkw084. View

2.
Persson R, Lee S, Yood M, Wagner M, Minton N, Niemcryk S . Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries. J Neurol. 2019; 266(5):1095-1106. PMC: 6469671. DOI: 10.1007/s00415-019-09238-8. View

3.
Persson R, Lee S, Ulcickas Yood M, Wagner Usn Mc C, Minton N, Niemcryk S . Infections in patients diagnosed with multiple sclerosis: A multi-database study. Mult Scler Relat Disord. 2020; 41:101982. DOI: 10.1016/j.msard.2020.101982. View

4.
Kingwell E, Zhu F, Evans C, Duggan T, Oger J, Tremlett H . Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study. Neuroepidemiology. 2019; 54(2):131-139. DOI: 10.1159/000504804. View

5.
Jick S, Li L, Falcone G, Vassilev Z, Wallander M . Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol. 2014; 261(8):1508-17. PMC: 4119255. DOI: 10.1007/s00415-014-7370-3. View